New antimicrobial approaches: Reuse of old drugs

Current Drug Targets

Volumn 17, Issue 6, 2016, Pages 731-738

  Savoia, Dianella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Anti protozoal activity; Antibacterial activity; Antifungal activity; Antiviral activity; Drug resistance; Old drugs; Tuberculosis

Indexed keywords

AMLODIPINE; AMPHOTERICIN B; ATORVASTATIN; AVERMECTIN B1 A; BEDAQUILINE; BUMETANIDE; CANDESARTAN; CARBIDOPA; DROSPIRENONE; EFLORNITHINE; ENTACAPONE; GALLIUM; ISONIAZID; IVERMECTIN; KETANSERIN; LEVOTHYROXINE; MEFLOQUINE; MILTEFOSINE; MINOCYCLINE; MOXIDECTIN; NICLOSAMIDE; PENTETIC ACID; PERHEXILINE; SELAMECTIN; STILBENE; TAMOXIFEN; THIORIDAZINE; TOLCAPONE; TOREMIFENE; UNINDEXED DRUG; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; NEUROLEPTIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BIOFILM; NONHUMAN; PROTEIN SYNTHESIS; TUBERCULOSIS; VIRUS REPLICATION; DRUG INDUSTRY; DRUG REPOSITIONING; ECONOMICS; HUMAN; PROCEDURES;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR AGENTS; DRUG INDUSTRY; DRUG REPOSITIONING; HUMANS;

EID: 84964089313     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150806124110     Document Type: Article

References (109)

1. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 8: 1-12.
2. Stanton TB. A call for antibiotic alternatives research. Trends Microbiol 2013; 21:111-13.
3. Head M G. Gross underinvestment in antibacterial research. Lancet Infect Dis 2014;14:788-9.
4. Theuretzbacher U. Resistance drives antibacterial drug development. Curr Opin Pharmacol 2011; 11: 433-8.
5. Livermore DM. Fourteen years in resistance. Intern J Antimicrob Agents 2012; 39: 283-94.
6. Laxminarayan R, Duse A, Chand W, et al. Antibiotic resistance - the need for global solutions. Lancet Infect Dis 2013; 13:1057-98.
7. Howard SJ, Catchpole M, Watson J, Davies SC. Antibiotic resistance: global response needed. Lancet Infect Dis 2013; 13: 1001-3.
8. Radhouani H, Silva N, Poeta P, et al. Potential impact of antimicrobial resistance in wildlife, environment, and human health. Front Microbiol 2014; 5: 23.
9. Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014; 14: 742-50.
10. Brown MG, Balkwill DL. Antibiotic resistance in bacteria isolated from the deep terrestrial subsurface. Microb Ecol 2009; 57: 484-93.
11. D’Costa VM, King CE, Kalan L, et al. Antibiotic resistance is ancient. Nature 2011; 477: 457-61.
12. Wright DG, Poinar H. Antibiotic resistance is ancient: implications for drug discovery. Trends Microbiol 2012; 20: 157-9.
13. Livermore RM on behalf of the British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: regenerating antibacterial drug discovery and development. J Antimicrob Chemother 2011; 66: 1941-4.
14. Ashburn T T, Thor K B. Drug repositioning. Identifying and developing new uses for existing drugs. Nature Rev Drug Discov 2004; 3: 673-83.
15. Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007; 448: 645-6.
16. Palomino JC, Martin A. Is repositioning drugs a viable alternative in the treatment of tuberculosis? J Antimicrob Chemother 2013; 68: 275-83.
17. Clark K B. Editorial: new therapeutic bearings for drug repositioning. Curr Top Med Chem 2013; 13: 2281-2.
18. Clark KB, Eisenstein EM, Krahl SE. Calcium antagonists: a ready prescription for treating infectious diseases? Curr Topics Medic Chem 2013; 13: 2291-305.
19. Clark K B. “The mating judgments of microbes,” In: Clark K B, Ed. Social Learning Theory: Phylogenetic Considerations across Animal, Plant, and Microbial Taxa. Hauppauge, NY: Nova Science Publishers Inc 2013; pp.173-200.
20. Amaral L, Viveiros M, Kristiansen JE. ‘Non-antibiotics’: alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr Drug Targets 2006; 7: 887-91.
21. Thanacoody HKR. Thioridazine: resurrection as an antimicrobial agent? Br J Clin Pharmacol 2007; 64: 566-74.
22. Martins M B W, Marko A, Ordway D, et al. Clinical concentrations of thioridazine enhance the killing of intracellular methicillinresistant Staphylococcus aureus: an in vivo, ex vivo and electron microscopy study. In Vivo 2004; 18: 787-94.
23. Ratnakar P, Murthy PS. Antitubercular activity of trifluoperazine, a calmodulin antagonist. FEMS Microbiol Lett 1992; 76: 73-6.
24. Weinstein EA, Yano T, Li LS, et al. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc Natl Acad Sci USA 2005; 102: 4548-53.
25. Gutierrez-Correa J. Trypanosoma cruzi dihydrolipoamide dehydrogenase as target for phenothiazine cationic radicals. Effect of antioxidants. Curr Drug Targets 2006; 7: 1155-79.
26. Rivarola HW, Paglini-Oliva PA. Trypanosoma cruzi trypanothione reductase inhibitors: phenothiazines and related compounds modify experimental Chagas' disease evolution. Curr Drug Targets Cardiovasc Haematol Disord 2002; 2: 43-52.
27. Pearson RD, Manian AA, Hall D, Harcus JL, Hewlett EL. Antileishmanial activity of chlorpromazine. Antimicrob Agents Chemother 1984; 25: 571-4.
28. Gracio MA, Gracio AJ, Viveiros M, Amaral L. Since phenothiazines alter antibiotic susceptibility of microorganisms by inhibiting efflux pumps, are these agents useful for evaluating similar pumps in phenothiazine-sensitive parasites? Int J Antimicrob Agents 2003; 22: 347-51.
29. Guttman P, Ehrlich P. Uber die Wirkung des Methylenblau bei Malaria. Berliner Klinika Wochenschrift 1891; 39: 953-6
30. Ehrlich P. Chemotherapeutics: scientific principles, methods, and results. Lancet 1913; 2: 445-51.
31. Amaral L, Viveiros M, Kristiansen JE. Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries. Trop Med Int Health 2001; 6: 1016-22.
32. Kristiansen JE, Hendricks O, Delvin T, et al. Reversal of resistance in microorganisms by help of non-antibiotics. J Antimicrob Chemother 2007; 59: 1271-9.
33. Singh S, Dinesh N, Kaur PK, Shamiulla B. Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3- hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani. Parasitol Res 2014; 113: 2161-216.
34. Nzila A, Okombo J, Becker RP, Chilengi R, Lang T, Niehues T: Anticancer agents against malaria: time to revisit? Trends Parasitol 2010; 26: 125-9.
35. Cragg GM, Grothaus PG, Newman DJ. New horizons for old drugs and drug leads. J Nat Prod 2014, 77, 703-23.
36. Collins F S. Mining for therapeutic gold. Nature Rev Drug Discov 2011; 10, 397.
37. Palomino JC, Ramos DF, da Silva PA. New anti-tuberculosis drugs: strategies, sources and new molecules. Curr Med Chem 2009; 16: 1898-904.
38. Butts A, Krysan D J. Antifungal drug discovery: something old and something new. PLoS Pathog 2012, 8, e1002870.
39. Grimberg BT, Mehlotra R K. Expanding the antimalarial drug arsenal-now, but how? Pharmaceuticals 2011; 4: 681-712.
40. Newman D J, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75: 311-35.
41. Looareesuwan S, Chulay J D, Canfield JC, Hutchinson DBA. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg 1999; 60: 533-41.
42. DeBoer C, Meulman P A, Wnuk R J, Peterson D H. Geldanamycin, a new antibiotic. J. Antibiot 1970; 23: 442-7.
43. Whitesell L, Mimnaugh EG, De Costa B, Myers C E, Neckers L M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994; 91: 8324-8.
44. Rochani A K, Singh M, Tatu U. Heat shock protein 90 inhibitors as broad spectrum anti- infectives. Curr Pharm Des 2013; 19: 377-86.
45. Palomino JC, Martin A. TMC207 becames bedaquiline, a new anti- TB drug. Future Microbiol 2013; 8: 1071-80.
46. Palomino JC, Martin A. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio. Curr Med Chem 2013; 20: 3785-96.
47. Maeda K, Kosaka H, Okami Y, Umezawa H. A new antiniotic, pyridomycin. J. Antibiot 1953, 6, 140.
48. Hartkoorn RC, Sala C, Neres J, et al. Towards a new tuberculosis drug: pyridomycin- nature’s isoniazid. EMBO Mol Med 2012; 4: 1032-42.
49. Wright G D. Back to the future: a new ‘old’ lead for tuberculosis. EMBO Mol Chem 2012; 4: 1029-31.
50. Huang T, Wang Y, Yin J, et al. Identification and characterization of the pyridomycin biosynthetic gene cluster of Streptomyces pyridomyceticus NRRL B-2517. J Biol Chem 2011; 286: 20648-57.
51. Gloeckner C, Garner AL, Mersha F, et al. Repositioning of an existing drug for the neglected tropical disease onchocerciasis. Proc Natl Acad Sci USA 2010; 107: 3424-9.
52. Lim LE, Vilchèze C, Ng C, et al. Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. Antimicrob Agents Chemother 2013; 57: 1040-6.
53. Jayaprakash S, Iso Y, Wan B et al. Design, synthesis, and SAR studies of mefloquine-based ligands as potential antituberculosis agents. Chem Med Chem 2006; 1: 593-7.
54. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrugresistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-6.
55. Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L, Bourne PE. Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol 2009; 5: e1000423.
56. Wainwright M. In defence of ‘dye therapy’. Intern J Antimicrob Agents 2014; 44: 26-9.
57. Boulos RA, Man NYT, Lengkeek NA. et al. Inspiration from old dyes: tris(stilbene) compounds as potent Gram-positive antibacterial agents. Chem Eur J 2013; 19: 17980-8.
58. Mazumdar K, Kumar KA, Dutta NK. Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: scope and hope for the future. Intern J Antimicrob Agents 2010; 36: 295-302.
59. Guo H, Ren B, Dai H. et al. Reversal of meticillin resi stance in Staphylococcus aureus by the anthelmintic avermectin. Int J Antimicrob Agents 2014; 44: 274-6.
60. Ooi N, Chopra I, Eady EA. et al. Antibacterial activity and mode of action of tert- butylhydroquinone (TBHQ) and its oxidative product, tert-butylbenzoquinone (TBBQ). J Antimicrob Chemother 2013; 68: 1297-304.
61. Ooi N, Eady EA, Cave JH, O’Neill AJ. Redox-active compounds with a history of human use: antistaphylococcal action and potential for repurposing as topical antibiofilm agent. J Antimicrob Chemother 2014; PMID 25368206.
62. Chromy BA, Elsheikh M, Christensen TL, et al. Repurposing screens identify rifamycins as potential broad-spectrum therapy for multi-drug-resistant Acinetobacter baumannii and select agent microorganisms. Future Microbiol 2012; 7: 1011-20.
63. Carlson-Banning KM, Chou A, Liu Z, et al. Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae. PLoS One 2013; 8: e69646.
64. Kelson AB, Carnevall M, Truong-Le V. Gallium-based antiinfectives: targeting microbial iron-uptake mechanisms. Curr Opin Pharmacol 2013; 13: 707-18.
65. Minandri F, Bonchi C, Frangipani F, Imperi F, Visca P. Promises and failures of gallium as an antibacterial agent. Future Microbiol 2014; 9: 379-97.
66. Frangipani E, Bonchi C, Minandri F, Imperi F, Visca P. Pyochelin potentiates the inhibitory activity of gallium on Pseudomonas aeruginosa. Antim Agents Chemother 2014; 58: 5572-5.
67. Gi M, Jeong J, Lee K. et al. A drug-repositioning screening identifies pentetic acid as a potential therapeutic agent suppressing the elastase-mediated virulence of Pseudomonas aeruginosa. Antim Agents Chemother 2014; 58: 7205-14.
68. Imperi F, Massai F, Ramachandran Pillai C, et al. New life fora n old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing. Antimicrob Agents Chemother 2013; 57: 996-1005.
69. Imperi F, Massai F, Facchini M, et al. Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity. PNAS 2013; 110: 7458-63.
70. Delattin N, De Brucher K, Vandamme K, et al. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilma. J Antimicrob Chemother 2014; 69: 1035-44.
71. Molyneux DH. Neglected tropical diseases: now more than just ‘other diseases’- the post- 2015 Agenda. Int Health 2014; 6: 172-80.
72. Allarakhia M. Open-source approached for the repurposing of existing or failed candidate drugs: learning from and applying the lesson across diseases. Drug Des Devel Ther 2013; 7: 753-66.
73. Bhardwaj A, Scaria V, Raghava GP, et al. Open source drug discovery a new paradigm of collaborative research in tuberculosis drug development. Tuberculosis (Edinburg) 2011; 91: 479-86.
74. Andrews KT, Fisher G, Skinner-Adams TS. Drug repurposing and human parasitic protozoan diseases. Intern J Parasitol Drugs Drug Resist 2014; 4: 95-111.
75. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg 2006; 100 (1): S26-S33.
76. Miguel DC, Yokoyama-Yasunaka JK, Andreoli WK, Mortara RA, Uliana SR. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J Antimicrob Chemother 2007; 60: 526-34.
77. Sanderson L, Yardley V, Croft SL. Activity of anti-cancer protein kinase inhibitors against Leishmania spp. J Antimicrob Chemother 2014; 69: 1888-91.
78. Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL. Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist 2012; 2: 11-9.
79. No authors listed.. One world problem, one world solution? Nature Rev Drug Discov 2005; 4: 701.
80. Sardana D, Zhu C, Zhang M, et al. Drug repositioning for orphan diseases. Brief Bioinform 2011; 12: 346-56.
81. Pollastri MP, Campbell RK. Target repurposing for neglected diseases. Future Med Chem 2011; 3: 1307-15.
82. Robertson SA, Renslo AR. Drug discovery for neglected tropical diseases at the Sandler Center. Future Med Chem 2011; 3: 1279-88.
83. Planer JD, Hulverson MA, Arif JA, et al. Synergy testing of FDAapproved drugs identifies potent drug combinations against Trypanosoma cruzi. PLoS Negl Trop Dis. 2014; 8: e2977.
84. Bellera CL, Balcazar DE, Alberca L, et al. Identification of levothyroxine antichagasic activity through computer-aided drug repurposing. Scientific World Journal 2014; 279618.
85. Matthews H, Usman-Idris M, Khan F, Read M, Nirmalan N. Drug repositioning as a route to anti-malarial drug discovery: preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate. Malaria J 2013; 12: 359.
86. Kadri D, Crater AK, Lee H, Solomon VR, Ananvoranich S. The potential of quinoline derivatives for the treatment of Toxoplasma gondii infection. Exp Parasitol 2014; 145: 135-44.
87. Boyom FF, Fokou PVT, Tchokouaha LRY, et al. Repurposing the Open Access Malaria Box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica. Antimicrob Agents Chemother 2014; 58: 5848-54.
88. Dutta K, Basu A. Use of minocycline in viral infections. Indian J Med Res 2011; 133: 467-70.
89. Ahmed A, Daneshtalab M. Nonclassical biological activities of quinolone derivatives. J Pharm Pharm Sci 2012; 15: 52-72.
90. Hu G, Li X, Sun X, et al. Identification of old drugs as potential inhibitors of HIV-1 integrase- human LEDGF/p75 interaction via molecular docking. J Mol Model 2012; 18: 4995-5003.
91. Mastrangelo E, Pezzullo M, De Burghgraeve T, et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Agents 2012; 67: 1884-94.
92. Madrid PB, Chopra S, Manger ID, et al. A systematic screen of DNA-approved drugs for inhibitors of biological threat agents. PLoS One 2013; 8: e60579.
93. Boonyasuppayakorn S, Reichert ED, Manzano M, Nagarajan K, Padmanabhan R. Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity. Antiviral Res 2014; 106: 125-34.
94. Johansen LM, Brannan JM, Delos SE, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 2013; 5: 190ra79.
95. Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of Middle East Respiratory Syndrome Coronavirus infection. Antimicrob Agents Chemother 2014; 58: 4885-93.
96. Tripp RA, Mark Tomkins S. Antiviral effects of inhibiting host gene expression. Curr Top Microbiol Immunol 2015; 386: 459-77.
97. Lotharius J, Gamo-Benito FJ, Angulo-Barturen I, et al. Repositioning: the fast track to new anti-malarial medicines? Malaria J 2014; 13: 143.
98. Mandapati K, Gorla SK, House AL, et al. Repurposing Cryptosporidium Inosine 5_- Monophosphate Dehydrogenase Inhibitors as Potential Antibacterial Agents. ACS Med Chem 2014; 5: 846-50.
99. Hedstrom L, Liechti G, Goldberg J B, Gollapalli D R. The antibiotic potential of prokaryotic IMP dehydrogenase inhibitors. Curr Med Chem 2011; 18: 1909-18.
100. Perlmutter JI, Forbes LT, Krysan DJ, et al. Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus. J Med Chem 2014; 57: 8540-62.
101. Seiler, N. Thirty years of polyamine-related approaches to cancer therapy. Retrospect. and prospect. Part I. Selective enzyme inhibitors. Curr Drug Targets 2003; 4: 537-64.
102. De bandt JP, Moinard C, Cynober L. Metabolisme et fonctions des polyamines. Immunoanal Biol Special 2006; 21: 333-41.
103. Chadwick J, Jones M, Mercer AE, et al. Design, synthesis and antimalarial/anticancer evaluation of spermidine linked artemisinin conjugates designed to exploit polyamine transporters in Plasmodium falciparum and HL-60 cancer cell lines. Bioorg Med Chem 2010; 18: 2586-97.
104. Shah P, Swiatlo EA. Multifaceted role for polyamines in bacterial pathogens. Mol Microbiol 2008; 68: 4-16.
105. Alhanout K, Brunel JM, Ranque S, Rolain JM. In vitro antifungal activity of aminosterols against moulds isolated from cystic fibrosis patients. J Antimicrob Chemother 2010; 65: 1307-9.
106. Bachrach U. Antiviral activity of oxidized polyamines. Amino Acids 2007; 33: 267-72.
107. Zasloff M, Adams AP, Beckerman B, et al. Squalamine as a broadspectrum systemic antiviral agent with therapeutic potential. Proc Natl Acad Sci USA 2011; 108: 15978-83.
108. Djouhri-Bouktab, Rolain JM, Brunel JM. Mini-Review: polyamines metabolism, toxicity and potent therapeutical use. Anti- Infective Agents 2014; 12: 95-103.
109. Cassir N, Rolain J-M, Broqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol 2014; 5: 551.